Similar Metabolic Response to Animal, Plant Protein Diets

Share this content:
Similar Metabolic Response to Animal, Plant Protein Diets
Similar Metabolic Response to Animal, Plant Protein Diets

MONDAY, Feb. 13, 2017 (HealthDay News) -- For patients with type 2 diabetes mellitus (T2DM), isocaloric diets high in animal protein (AP) or plant protein (PP) are associated with similar improvements in metabolism and cardiovascular risk factors, according to a study published online Feb. 9 in Diabetes, Obesity and Metabolism.

Stephanie Sucher, from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal, and colleagues compared diets differing in amino acid composition in 44 patients with T2DM. Isocaloric diets containing 30 percent of energy as AP or PP, combined with 30 percent fat and 40 percent carbohydrates, were compared in a randomized parallel group study.

The researchers observed significant decreases in uric acid in both groups, but significantly more in AP versus PP. There were significant improvements in hemoglobin A1c, diastolic blood pressure, and fasting non-esterified fatty acids in PP but not AP. There were significant improvements in AP but not PP for insulin sensitivity, C-reactive protein, and fasting glucose. In both groups, total and low-density lipoprotein cholesterol decreased significantly, and there was a decrease from baseline in urinary albumin excretion rate in microalbuminuric subjects.

"Isocaloric diets high in animal or plant protein allow similar improvements of metabolism and cardiovascular risk factors in T2DM patients indicating that the differences in amino acid composition do not affect the metabolic responses to the interventions," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »